Table 1

The antibodies used in this study and their results
Antibody ACC HGT
Antigens Clone Source Cribriform Solid
EMA E29 DakoCytomation (Carpinteria, CA, USA) + + ++
GCDFP-15 NCL-GCDFP15 Novocastra Laboratories Ltd. (New Castle Upon Tyne, UK) - - -
Her-2 DakoCytomation (Carpinteria CA) - 1+ 3+
EGFR NCL-L-EGFR Novocastra Laboratories Ltd. (New Castle Upon Tyne, UK) - - -
AR AR441 DakoCytomation (Carpinteria, CA, USA) - - -
CK5/6 D5/16 B4 DakoCytomation (Carpinteria, CA, USA) + + -(myo+)
S-100 DakoCytomation (Carpinteria, CA, USA) + + -
ASMA 1A4 DakoCytomation (Carpinteria, CA, USA) ++ + -
calponin CALP DakoCytomation (Carpinteria, CA, USA) + f+ -
CK14 LL002 Chemicon International (Temecula, CA, USA) + p+ -(myo+)
p63 4A4 Lab Vision (Fremont, CA, USA) ++ p+ -(myo+)
mammaglobin 304-1A5 DakoCytomation (Carpinteria, CA, USA) - f+
p53 DO-7 DakoCytomation (Carpinteria, CA, USA) f+ p+ ++
cyclin A NCL-CYCLN A Novocastra Laboratories Ltd. (New Castle Upon Tyne, UK) 10.3% 17.3% 34.5%
cyclin B1 NCL-CYCLN B1 Novocastra Laboratories Ltd. (New Castle Upon Tyne, UK) 0.5% 12.2% 50.3%
cyclin D1 DSC-6 DakoCytomation (Carpinteria CA, USA) - 1.1% -
cylcin E NCL-CYCLN E Novocastra Laboratories Ltd. (New Castle Upon Tyne, UK) - - -
p16 G175-405 BD Biosciences (Franklin Lakes, NJ, USA) f+ p+ ++
MDM2 SMP14 Themo Fisher Scientific (Cheshire, UK) - - -
Ki-67L.I. MIB-1 DakoCytomation (Carpinteria, CA, USA) 34.5% 49.7% 73.2%

ACC, adenoid cystic carcinoma area; HGT, high-grade transformation area.

EMA, epithelial membrane antigen; GCDFP-15, gross cystic disease fluid protein-15; EGFR. Epidermal growth factor receptor; AR, androgen receptor; CK, cytokeratin; ASMA, alpha-smooth muscle actin.

—, negative; f+, focally positive (1-9%); p+, partially positive (10-19%); +, positive (20-60%); ++, diffusely positive (>60%); myo, myoepithelial cells.

Kusafuka et al.

Kusafuka et al. Diagnostic Pathology 2013 8:113   doi:10.1186/1746-1596-8-113

Open Data